Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Pfizer Rheumatoid Arthritis Drug Beats Older Treatment in Study

Don't Miss Out —
Follow us on:

July 31 (Bloomberg) -- Pfizer Inc. said its rheumatoid arthritis treatment tofacitinib, one of the company’s leading experimental drugs, was more effective than an older treatment in a large-scale study.

The drug met its primary end-point in the study and no new side effects were found, Pfizer said today in a statement. Pfizer said on a conference call with analysts today that the Food and Drug Administration may need more time than expected to make a decision on approval of the treatment.

The study, dubbed ORAL start, found that tofacitinib was superior to methotrexate in easing pain and swelling of joints caused by rheumatoid arthritis, according to the statement. Results were from the last of three stages of human tests generally required for FDA approval.

Rheumatoid arthritis is a chronic inflammatory disorder that affects about 1.3 million Americans and 23.7 million people worldwide, the company said in the statement.

Pfizer shares jumped 2 percent to $24.19 at 10:44 a.m. in New York trading.

To contact the reporter responsible for this story: Shannon Pettypiece at spettypiece@bloomberg.net.

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.